Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
← catalyst calendarNCT03878849 · readout ≤ 224 d
Sponsored by Allarity Therapeutics (industry) · ALLR — their whole pipeline →. With Alcedis GmbH, Amarex Clinical Research.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
40estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-04-15 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2019-03-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Ovarian Cancer
Interventions
- Drug: 2X-121 — also filed as E7449, MGI25036
- Drug: 2X-121
Primary outcome
what the primary-completion date above is the date OFEvaluate the optimal dose of 2X-121 as single agent therapy
measured From enrollment up to approximately 2 years
Permalink · ALLR's whole pipeline · Catalyst calendar · Every registered study · What changed